FDA Premarket Safety Plan Is Not Cost-Effective – PhRMA
This article was originally published in The Tan Sheet
Safety requirements outlined in FDA's "Premarketing Risk Assessment" concept paper seem to run counter to cost-effective drug development, which has been stressed by Commissioner Mark McClellan, MD/PhD, PhRMA said during a public workshop on risk management in Washington, D.C. April 9
You may also be interested in...
Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Perrigo promotes in pricing, planning